Downtrend on the daily chart: below its 200-day average, above its 50-day · 50-day below the 200-day · SuperTrend down since Oct 12 · below the Ichimoku cloud · RSI 53 · MACD above its signal
None of the 29 investors followed here reported a position in ENTBF in their latest filing.
From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors
No member of Congress has disclosed a ENTBF trade since 2025.
From House and Senate STOCK Act reports. Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades
No insider transactions reported for ENTBF.
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | -94.9 | 0.0 | 850.0 | -89.5 | 400.0 | −74.7% | ||
| 2025 | 79.6 | -30.5 | -49.7 | -5.8 | -21.0 | -14.1 | 36.4 | -8.0 | 7.2 | -9.5 | -11.9 | 33.9 | −42.3% |
| 2024 | 14.3 | 12.5 | 93.3 | -21.3 | -12.4 | -9.2 | -11.0 | 17.5 | -50.9 | 42.9 | 25.0 | 37.0 | +95.7% |
| 2023 | 92.3 | -12.0 | -9.1 | 15.0 | 0.0 | 8.7 | -24.0 | -15.8 | -12.5 | -42.9 | 0.0 | -12.5 | −46.2% |
| 2022 | -24.6 | -20.0 | -34.2 | -29.0 | -28.2 | -33.3 | 11.8 | 28.9 | -30.6 | -26.5 | 4.0 | -50.0 | −94.8% |
| 2021 | -7.1 | -18.5 | -20.9 | -27.2 | 9.5 | -21.0 | 14.0 | -30.2 | 77.6 | 7.5 | -37.2 | −64.0% |
No analyst coverage for this instrument.
Entheon Biomedical Corp. operates as a biotechnology research and development company. It develops products for treating addiction and substance use disorders. Entheon Biomedical Corp. is headquartered in Vancouver, Canada.